Sign in
TerminatedNo phase

ScentAware and OCT in MCI vs HC

Key facts

Who runs it
University of Wisconsin, Madison
Where
Madison, United StatesSee the site
Trial code
Status
Terminated
People taking part
20 people enrolled
Started
15 Apr 2024
Ended
5 Jun 2024
Type of study
Observational, 3 groups
Treatments tested
  • ScentAware
  • UPSIT
Record updated
23 April 2025
Why it stopped
slow enrollment

Who can take part

Age
50 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Adults who are ≥ 50 and ≤ 80 years of age
  • Fluent in English
  • Able to provide written consent
  • Able to complete a 2.5-3-hour clinical visit, including sitting for spectral domain optical coherence tomography (SD-OCT) imaging for 30 minutes and taking cognitive and olfactory tests for 90-120 minutes
  • Cognitive Ability and Family History of Alzheimer's Disease/Mild Cognitive Impairment (AD/MCI):; Cohort 1: Cognitively unimpaired, no family history of MCI or AD, and MMSE ≥ 26; Cohort 2: Cognitively unimpaired, a positive family history of MCI or AD, and MMSE ≥ 26; Cohort 3: An MMSE score > 22 and ≤ 25 and either; Clinically diagnosed MCI due to AD; A participant in a Wisconsin ADRC research registry with either clinically diagnosed MCI or self-reported MCI
  • Cohorts 1 and 2: proficient in independent use of mobile smart devices

Who cannot take part

  • A cataract extraction within 3 months prior to enrollment
  • Current use of medications that may interfere with olfactory functions
  • A history of significant ocular or nasal trauma that required medical/surgical intervention
  • A history of intraocular surgery except cataract extraction
  • A history of recurrent or chronic oto-pharyngeal-laryngeal (ORL) disease (such as chronic rhinitis, nasal polyposis, or sinus disease), head trauma, toxic exposures, upper respiratory infections at time of assessment
  • A family history or diagnosis of other neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease) or conditions that, in the opinion of the Investigators, may affect cognitive or olfactory functions
  • Olfactory loss due to COVID (current olfactory loss and/or temporary loss that has been regained)
  • Diagnosis of visually significant intraocular disease (such as late-stage age-related macular degeneration, glaucoma, or other optic nerve conditions related to brain tumor or multiple sclerosis), drug related vision loss or retinal damage
  • Optic neuritis on both eyes
  • Current use of hydroxychloroquine and tamoxifen, which are known to cause retinal toxicity that may confound OCT interpretation

Where in United States

  • University of WisconsinMadison, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are:

Read full original descriptionShow less

* Whether the test is as effective and reliable as the standard test * Whether there is a link between the results of the smell test and the structure of the back of the eye

Participants will:

* complete a short questionnaire * have pictures of the inside of their eyes taken * perform two smell tests

The 3 groups in the trial

  • Cohort 1

    No cognitive impairment, and no family history of Alzheimer's disease

    Treatment: ScentAware and UPSIT

  • Cohort 2

    No cognitive impairment, with a family history of Alzheimer's disease

    Treatment: ScentAware and UPSIT

  • Cohort 3

    Mild cognitive impairment due to Alzheimer's disease

    Treatment: ScentAware and UPSIT

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Proof-of-concept Pilot Study to Determine the Efficacy of SensifyAware and Retinal Imaging in Differentiating Mild Cognitive Impairment (MCI) From Cognitively Unimpaired Controls (HC)
Record updated
23 April 2025